BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

The Medicines Company (MDCO) Release: British Medical Leaders Report Results of Global Heart Attack Study


6/16/2011 9:58:19 AM

OXFORDSHIRE, ENGLAND--(Marketwire - June 16, 2011) - Professor Stuart J. Pocock of the London School of Hygiene and Tropical Medicine was lead statistician and co-author of a heart attack study published this week by The Lancet, a London-based peer reviewed medical journal.

The article reviewed the final three year results of a clinical trial called HORIZONS-AMI that was conducted globally in 3,602 heart attack patients, 102 of whom were treated in the United Kingdom. The authors span three continents, six countries and five native languages.

"Heart attacks continue to be the most frequent killer in the world," said Dr. Clive Meanwell, entrepreneur, health science innovator and chief executive of The Medicines Company, which provided research grant support for the study. "Investigators -- including experts from the United Kingdom -- have demonstrated with this study that global multidisciplinary collaboration enables a potential step forward in healthcare."

HORIZONS-AMI findings affected revisions to heart attack treatment guidelines published by the European Society for Cardiology (ESC) and the British Cardiovascular Society in 2010. In England and Wales, according to the Office for National Statistics, about 31,283 people die from heart attacks in 2007.

The Lancet article is the final of primary HORIZONS-AMI analyses published in major peer reviewed journals at 30 days, 1 year, 2 years and now 3 years of patient follow-up after their procedure. There have also been more than 60 secondary analyses published examining results in patient sub-populations. The latest was an analysis of patients who had drug therapies switched in the course of their treatment and was published in the Journal of the American College of Cardiology last week.


Contact:
Michael Mitchell
The Medicines Company
+973-290-6000
corporate.communications@themedco.com


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->